INDICATION

ABECMA (idecabtagene vicleucel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

This website is best viewed using the horizontal display on your tablet device.

This website is best viewed using the vertical display on your mobile device.

PFS Analyses Across a Broad Set of Patient Subgroups1

Analysis limitations: These analyses are exploratory in nature and definitive conclusions should not be drawn.

ORR Subgroup Graphic
0.51 (0.39-0.66)
All subjects
149/254
93/132
Total patient population
N
ORR
LCL
UCL
0
10
20
30
40
50
60
70
80
90
100
 
100
72
62
81
Age group
HR (95% CI)
ABECMA®
Standard
Regimens
0.0
0.4
0.8
1.2
1.6
2.0
2.4
2.8
Age group: <65
 
0.57 (0.40-0.80)
93/150
51/78
Age group: ≥65
 
0.43 (0.28-0.64)
56/104
42/54
Age group: 65-74
 
0.42 (0.27-0.65)
49/92
36/45
Age group: 75-84
 
0.59 (0.19-1.78)
7/12
6/9
Region
HR (95% CI)
ABECMA
Standard
Regimens
0.0
0.4
0.8
1.2
1.6
2.0
2.4
2.8
Region: North America
 
0.50 (0.36-0.70)
84/144
60/82
Region: Europe
.
 
0.44 (0.28-0.68)
63/106
32/45
Region: Japan
.
 
NC
2/4
1/5
Sex / Race / Ethnicity
HR (95% CI)
ABECMA
Standard
Regimens
0.0
0.4
0.8
1.2
1.6
2.0
2.4
2.8
Sex: Male
 
0.53 (0.38-0.75)
92/156
55/79
Sex: Female
.
 
0.47 (0.31-0.71)
57/98
38/53
Sex / Race / Ethnicity
HR (95% CI)
ABECMA
Standard
Regimens
0.0
0.4
0.8
1.2
1.6
2.0
2.4
2.8
Race: White
 
0.52 (0.37-0.73)
101/172
54/78
Race: Non-white
 
0.59 (0.29-1.22)
14/28
18/27
Sex / Race / Ethnicity
HR (95% CI)
ABECMA
Standard
Regimens
0.0
0.4
0.8
1.2
1.6
2.0
2.4
2.8
Race: White
 
0.52 (0.37-0.73)
101/172
54/78
Race: Asian
 
NC
4/7
1/5
Race: African American
 
0.50 (0.20-1.23)
8/18
13/18
Race: Other
 
NC
2/3
4/4
Sex / Race / Ethnicity
HR (95% CI)
ABECMA
Standard
Regimens
0.0
0.4
0.8
1.2
1.6
2.0
2.4
2.8
Ethnicity: Hispanic or Latino
 
0.21 (0.05-0.93)
5/11
5/8
Ethnicity: Not Hispanic or Latino
 
0.56 (0.41-0.76)
109/188
68/98
Anti-CD38 class refractory
HR (95% CI)
ABECMA
Standard
Regimens
0.0
0.4
0.8
1.2
1.6
2.0
2.4
2.8
Anti-CD38 class refractory: Yes
 
0.51 (0.39-0.67)
143/242
88/124
Anti-CD38 class refractory: No
 
0.40 (0.11-1.40)
6/12
5/8
Daratumumab refractory
HR (95% CI)
ABECMA
Standard
Regimens
0.0
0.4
0.8
1.2
1.6
2.0
2.4
2.8
Daratumumab refractory: Yes
 
0.51 (0.39-0.67)
143/242
88/123
Daratumumab refractory: No
 
0.40 (0.11-1.40)
6/12
65/9
Double-class (immunomodulatory
agent and PI) refractory
HR (95% CI)
ABECMA
Standard
Regimens
0.0
0.4
0.8
1.2
1.6
2.0
2.4
2.8
Double-class (immunomodulatory agent and PI)
refractory: Yes
 
0.47 (0.34-0.63)
106/169
72/91
Double-class (immunomodulatory agent and PI)
refractory: No
 
0.65 (0.38-1.11)
43/85
21/41
Triple-class refractory
HR (95% CI)
ABECMA
Standard
Regimens
0.0
0.4
0.8
1.2
1.6
2.0
2.4
2.8
Triple-class refractory: Yes
 
0.46 (0.34-0.62)
103/164
70/89
Triple-class refractory: No
 
0.65 (0.39-1.09)
46/90
23/43
Penta-refractory
HR (95% CI)
ABECMA
Standard
Regimens
0.0
0.4
0.8
1.2
1.6
2.0
2.4
2.8
Penta-refractory: Yes
 
0.63 (0.17-2.33)
12/15
3/5
Penta-refractory: No
 
0.49 (0.37-0.64)
137/239
90/127
R-ISS stage at baseline
HR (95% CI)
ABECMA
Standard
Regimens
0.0
0.4
0.8
1.2
1.6
2.0
2.4
2.8
R-ISS stage at baseline: I or II
 
0.48 (0.36-0.64)
113/200
78/108
R-ISS stage at baseline: III
 
0.86 (0.39-1.92)
27/31
8/14
Tumor burden
HR (95% CI)
ABECMA
Standard
Regimens
0.0
0.4
0.8
1.2
1.6
2.0
2.4
2.8
Tumor burden: <50%
 
0.47 (0.34-0.65)
99/172
60/90
Tumor burden: ≥50%
 
0.60 (0.37-0.97)
44/71
28/34
Extramedullary plasmacytoma
HR (95% CI)
ABECMA
Standard
Regimens
0.0
0.4
0.8
1.2
1.6
2.0
2.4
2.8
Extramedullary plasmacytoma: Yes
 
0.40 (0.25-0.65)
48/61
28/32
Extramedullary plasmacytoma: No
 
0.51 (0.37-0.70)
100/192
65/100
Number of prior anti-myeloma regimens
HR (95% CI)
ABECMA
Standard
Regimens
0.0
0.4
0.8
1.2
1.6
2.0
2.4
2.8
Number of prior anti-myeloma regimens: 2
 
0.51 (0.31-0.84)
41/78
26/39
Number of prior anti-myeloma regimens: 3 or 4
 
0.51 (0.37-0.69)
108/176
67/93
Number of prior anti-myeloma regimens
HR (95% CI)
ABECMA
Standard
Regimens
0.0
0.4
0.8
1.2
1.6
2.0
2.4
2.8
Number of prior anti-myeloma regimens: 2
 
0.51 (0.31-0.84)
41/78
26/39
Number of prior anti-myeloma regimens: 3
 
0.44 (0.29-0.68)
57/95
37/49
Number of prior anti-myeloma regimens: 4
 
0.58 (0.36-0.92)
51/81
30/44
High-risk cytogenetic abnormalities
HR (95% CI)
ABECMA
Standard
Regimens
0.0
0.4
0.8
1.2
1.6
2.0
2.4
2.8
High-risk cytogenetic abnormalities: Presence
 
0.61 (0.41-0.90)
65/107
42/61
High-risk cytogenetic abnormalities:
Absence or unknown
 
0.44 (0.31-0.63)
84/147
51/71

The standard regimens consisted of 5 antimyeloma treatment options: DPd, DVd, IRd, Kd, or EPd, selected by Investigator contingent upon the patient’s most recent antimyeloma treatment.2

Efficacy based on follow-up at the primary PFS analysis (median follow-up of 15.9 months (95% CI: 14.1, 18.0)).2

DPd=daratumumab, pomalidomide, dexamethasone; DVd=daratumumab, bortezomib, dexamethasone; EPd=elotuzumab, pomalidomide, dexamethasone; HR=hazard ratio; IRd=ixazomib, lenalidomide, dexamethasone; Kd=carfilzomib, dexamethasone; NC=not calculated; PFS=progression-free survival; PI=proteasome inhibitor; R-ISS=Revised International Staging System.


Identify your
ABECMA-eligible patients

LEARN MORE

Start the ABECMA
process faster
than
ever—find a certified
treatment center
near you

SEARCH NOW

Back to top

INDICATION

ABECMA (idecabtagene vicleucel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

IMPORTANT SAFETY INFORMATION

WARNING: CYTOKINE RELEASE SYNDROME, NEUROLOGIC TOXICITIES, HLH/MAS, PROLONGED CYTOPENIA and SECONDARY HEMATOLOGICAL MALIGNANCIES

  • Cytokine Release Syndrome (CRS), including fatal or life-threatening reactions, occurred in patients following treatment with ABECMA. Do not administer ABECMA to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab or tocilizumab and corticosteroids.
  • Neurologic Toxicities, which may be severe or life-threatening, occurred following treatment with ABECMA, including concurrently with CRS, after CRS resolution, or in the absence of CRS. Monitor for neurologic events after treatment with ABECMA. Provide supportive care and/or corticosteroids as needed.
  • Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS) including fatal and life-threatening reactions, occurred in patients following treatment with ABECMA. HLH/MAS can occur with CRS or neurologic toxicities.
  • Prolonged Cytopenia with bleeding and infection, including fatal outcomes following stem cell transplantation for hematopoietic recovery, occurred following treatment with ABECMA.
  • T cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19-directed genetically modified autologous T cell immunotherapies, including ABECMA
  • ABECMA is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the ABECMA REMS.

Warnings and Precautions:
Early Death: In KarMMa-3, a randomized (2:1), controlled trial, a higher proportion of patients experienced death within 9 months after randomization in the ABECMA arm (45/254; 18%) compared to the standard regimens arm (15/132; 11%). Early deaths occurred in 8% (20/254) and 0% prior to ABECMA infusion and standard regimen administration, respectively, and 10% (25/254) and 11% (15/132) after ABECMA infusion and standard regimen administration, respectively. Out of the 20 deaths that occurred prior to ABECMA infusion, 15 occurred from disease progression, 3 occurred from adverse events and 2 occurred from unknown causes. Out of the 25 deaths that occurred after ABECMA infusion, 10 occurred from disease progression, 11 occurred from adverse events, and 4 occurred from unknown causes.

Cytokine Release Syndrome (CRS): CRS, including fatal or life-threatening reactions, occurred following treatment with ABECMA. Among patients receiving ABECMA for relapsed refractory multiple myeloma in the KarMMa and KarMMa-3 studies (N=349), CRS occurred in 89% (310/349), including ≥ Grade 3 CRS (Lee grading system) in 7% (23/349) of patients and Grade 5 CRS in 0.9% (3/349) of patients. The median time-to-onset of CRS, any grade, was 1 day (range: 1 to 27 days), and the median duration of CRS was 5 days (range: 1 to 63 days). In the pooled studies, the rate of ≥Grade 3 CRS was 10% (7/71) for patients treated in dose range of 460 to 510 x 106 CAR-positive T cells and 5.4% (13/241) for patients treated in dose range of 300 to 460 x 106 CAR-positive T cells.

The most common manifestations of CRS (greater than or equal to 10%) included pyrexia (87%), hypotension (30%), tachycardia (26%), chills (19%), hypoxia (16%). Grade 3 or higher events that may be associated with CRS include hypotension, hypoxia, hyperbilirubinemia, hypofibrinogenemia, ARDS, atrial fibrillation, hepatocellular injury, metabolic acidosis, pulmonary edema, coagulopathy, renal failure, multiple organ dysfunction syndrome and HLH/MAS.

Identify CRS based on clinical presentation. Evaluate for and treat other causes of fever, hypoxia, and hypotension. CRS has been reported to be associated with findings of HLH/MAS, and the physiology of the syndromes may overlap. HLH/MAS is a potentially life-threatening condition. In patients with progressive symptoms of CRS or refractory CRS despite treatment, evaluate for evidence of HLH/MAS.

Of the 349 patients who received ABECMA in clinical trials, 226 (65%) patients received tocilizumab; 39% (135/349) received a single dose, while 26% (91/349) received more than 1 dose of tocilizumab. Overall, 24% (82/349) of patients received at least 1 dose of corticosteroids for treatment of CRS. Almost all patients who received corticosteroids for CRS also received tocilizumab. For patients treated in dose range of 460 to 510 x 106 CAR-positive T cells, 76% (54/71) of patients received tocilizumab and 35% (25/71) received at least 1 dose of corticosteroids for treatment of CRS. For patients treated in dose range of 300 to 460 x 106 CAR-positive T cells, 63% (152/241) of patients received tocilizumab and 20% (49/241) received at least 1 dose of corticosteroid for treatment of CRS.

Monitor patients at least daily for 7 days following ABECMA infusion at the REMS-certified healthcare facility for signs or symptoms of CRS and monitor patients for signs or symptoms of CRS for at least 4 weeks after ABECMA infusion. At the first sign of CRS, institute treatment with supportive care, tocilizumab and/or corticosteroids as indicated. Ensure that a minimum of 2 doses of tocilizumab are available prior to infusion of ABECMA. Counsel patients to seek immediate medical attention should signs or symptoms of CRS occur at any time.

Neurologic Toxicities: Neurologic toxicities, including immune-effector cell-associated neurotoxicity (ICANS), which may be severe or life-threatening, occurred concurrently with CRS, after CRS resolution, or in the absence of CRS following treatment with ABECMA.

In patients receiving ABECMA in the KarMMa and KarMMa-3 studies, CAR T cell-associated neurotoxicity occurred in 40% (139/349), including Grade 3 in 4% (14/349) and Grade 4 in 0.6% (2/349) of patients. The median time to onset of neurotoxicity was 2 days (range: 1 to 148 days). The median duration of CAR T cell-associated neurotoxicity was 8 days (range: 1 to 720 days) in all patients including those with ongoing neurologic events at the time of death or data cut off. CAR T cell-associated neurotoxicity resolved in 123 of 139 (88%) patients and median time to resolution was 5 days (range: 1 to 245 days). One-hundred and thirty four out of 349 (38%) patients with neurotoxicity had CRS. The onset of neurotoxicity during CRS was observed in 93 patients, before the onset of CRS in 12 patients, and after the CRS event in 29 patients. The rate of Grade 3 or 4 CAR T cell-associated neurotoxicity was 5.6% (4/71) and 3.7% (9/241) for patients treated in dose range of 460 to 510 x 106 CAR-positive T cells and 300 to 460 x 106 CAR-positive T cells, respectively. The most frequent (greater than or equal to 5%) manifestations of CAR T cell-associated neurotoxicity include encephalopathy (21%), headache (15%), dizziness (8%), delirium (6%), and tremor (6%).

At the safety update for KarMMa-3 study, one patient developed fatal neurotoxicity 43 days after ABECMA. In KarMMa, one patient had ongoing Grade 2 neurotoxicity at the time of death. Two patients had ongoing Grade 1 tremor at the time of data cutoff.

Cerebral edema has been associated with ABECMA in a patient in another study in multiple myeloma. Grade 3 myelitis and Grade 3 parkinsonism have occurred after treatment with ABECMA in another study in multiple myeloma.

Monitor patients at least daily for 7 days following ABECMA infusion at the REMS-certified healthcare facility for signs or symptoms of neurologic toxicities and monitor patients for signs or symptoms of neurologic toxicities for at least 4 weeks after ABECMA infusion and treat promptly. Rule out other causes of neurologic symptoms. Neurologic toxicity should be managed with supportive care and/or corticosteroids as needed. Counsel patients to seek immediate medical attention should signs or symptoms occur at any time.

Hemophagocytic Lymphohistiocytosis (HLH)/Macrophage Activation Syndrome (MAS): In patients receiving ABECMA in the KarMMa and KarMMa-3 studies, HLH/MAS occurred in 2.9% (10/349) of patients. All events of HLH/MAS had onset within 10 days of receiving ABECMA, with a median onset of 6.5 days (range: 4 to 10 days) and occurred in the setting of ongoing or worsening CRS. Five patients with HLH/MAS had overlapping neurotoxicity. The manifestations of HLH/MAS include hypotension, hypoxia, multiple organ dysfunction, renal dysfunction and cytopenia.

In KarMMa-3, one patient had Grade 5, two patients had Grade 4 and two patients had Grade 3 HLH/MAS. The patient with Grade 5 HLH/MAS also had Grade 5 candida sepsis and Grade 5 CRS. In another patient who died due to stroke, the Grade 4 HLH/MAS had resolved prior to death. Two cases of Grade 3 and one case of Grade 4 HLH/MAS had resolved.

In KarMMa, one patient treated in the 300 x 106 CAR-positive T cells dose cohort developed fatal multi-organ HLH/MAS with CRS. In another patient with fatal bronchopulmonary aspergillosis, HLH/MAS was contributory to the fatal outcome. Three cases of Grade 2 HLH/MAS resolved.

HLH/MAS is a potentially life-threatening condition with a high mortality rate if not recognized early and treated. Treatment of HLH/MAS should be administered per institutional guidelines.

ABECMA REMS: Due to the risk of CRS and neurologic toxicities, ABECMA is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the ABECMA REMS. Further information is available at www.AbecmaREMS.com or contact Bristol-Myers Squibb at 1-866-340-7332.

Hypersensitivity Reactions: Allergic reactions may occur with the infusion of ABECMA. Serious hypersensitivity reactions, including anaphylaxis, may be due to dimethyl sulfoxide (DMSO) in ABECMA.

Infections: ABECMA should not be administered to patients with active infections or inflammatory disorders. Severe, life-threatening, or fatal infections occurred in patients after ABECMA infusion.

In all patients receiving ABECMA in the KarMMa and KarMMa-3 studies, infections (all grades) occurred in 61% of patients. Grade 3 or 4 infections occurred in 21% of patients. Grade 3 or 4 infections with an unspecified pathogen occurred in 12%, viral infections in 7%, bacterial infections in 4.3%, and fungal infections in 1.4% of patients. Overall, 15 patients had Grade 5 infections (4.3%); 8 patients (2.3%) with infections of pathogen unspecified, 3 patients (0.9%) with fungal infections, 3 patients (0.9%) with viral infections, and 1 patient (0.3%) with bacterial infection.

Monitor patients for signs and symptoms of infection before and after ABECMA infusion and treat appropriately. Administer prophylactic, pre-emptive, and/or therapeutic antimicrobials according to standard institutional guidelines.

Febrile neutropenia was observed in 38% (133/349) of patients after ABECMA infusion and may be concurrent with CRS. In the event of febrile neutropenia, evaluate for infection and manage with broad-spectrum antibiotics, fluids, and other supportive care as medically indicated.

Viral Reactivation: Cytomegalovirus (CMV) infection resulting in pneumonia and death has occurred following ABECMA administration. Monitor and treat for CMV reactivation in accordance with clinical guidelines. Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, can occur in patients treated with drugs directed against plasma cells. Perform screening for CMV, HBV, hepatitis C virus (HCV), and human immunodeficiency virus (HIV) in accordance with clinical guidelines before collection of cells for manufacturing. Consider antiviral therapy to prevent viral reactivation per local institutional guidelines/clinical practice.

Prolonged Cytopenias: In patients receiving ABECMA in the KarMMa and KarMMa-3 studies, 40% of patients (139/349) experienced prolonged Grade 3 or 4 neutropenia and 42% (145/349) experienced prolonged Grade 3 or 4 thrombocytopenia that had not resolved by Month 1 following ABECMA infusion. In 89% (123/139) of patients who recovered from Grade 3 or 4 neutropenia after Month 1, the median time to recovery from ABECMA infusion was 1.9 months. In 76% (110/145) of patients who recovered from Grade 3 or 4 thrombocytopenia, the median time to recovery was 1.9 months. Five patients underwent stem cell therapy for hematopoietic reconstitution due to prolonged cytopenia. The rate of Grade 3 or 4 thrombocytopenia was 62% (44/71) and 56% (135/241) for patients treated in dose range of 460 to 510 x 106 CAR-positive T cells and 300 to 460 x 106 CAR-positive T cells, respectively.

Monitor blood counts prior to and after ABECMA infusion. Manage cytopenia with myeloid growth factor and blood product transfusion support according to local institutional guidelines.

Hypogammaglobulinemia: In all patients receiving ABECMA in the KarMMa and KarMMa-3 studies, hypogammaglobulinemia was reported as an adverse event in 13% (46/349) of patients; laboratory IgG levels fell below 500 mg/dL after infusion in 37% (130/349) of patients treated with ABECMA.

Hypogammaglobulinemia either as an adverse reaction or laboratory IgG level below 500 mg/dL after infusion occurred in 45% (158/349) of patients treated with ABECMA. Forty-one percent of patients received intravenous immunoglobulin (IVIG) post-ABECMA for serum IgG <400 mg/dL.

Monitor immunoglobulin levels after treatment with ABECMA and administer IVIG for IgG <400 mg/dl. Manage appropriately per local institutional guidelines, including infection precautions and antibiotic or antiviral prophylaxis.

Use of Live Vaccines: The safety of immunization with live viral vaccines during or after ABECMA treatment has not been studied. Vaccination with live virus vaccines is not recommended for at least 6 weeks prior to the start of lymphodepleting chemotherapy, during ABECMA treatment, and until immune recovery following treatment with ABECMA.

Secondary Malignancies: Patients treated with ABECMA may develop secondary malignancies. In KarMMa-3, myeloid neoplasms (four cases of myelodysplastic syndrome and one case of acute myeloid leukemia) occurred in 2.2% (5/222) of patients following treatment with ABECMA compared to none in the standard regimens arm at the time of the safety update. The median time to onset of myeloid neoplasm from ide-cel infusion was 338 days (Range: 277 to 794 days). Three of these five patients have died following the development of myeloid neoplasm. One out of the five cases of myeloid neoplasm occurred after initiation of subsequent antimyeloma therapy.

T cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19-directed genetically modified autologous T cell immunotherapies, including ABECMA. Mature T cell malignancies, including CAR-positive tumors, may present as soon as weeks following infusion, and may include fatal outcomes.

Monitor life-long for secondary malignancies. In the event that a secondary malignancy occurs, contact Bristol-Myers Squibb at 1-888-805-4555 for reporting and to obtain instructions on collection of patient samples for testing of secondary malignancy.

Effects on Ability to Drive and Operate Machinery: Due to the potential for neurologic events, including altered mental status or seizures, patients receiving ABECMA are at risk for altered or decreased consciousness or coordination in the 8 weeks following ABECMA infusion. Advise patients to refrain from driving and engaging in hazardous occupations or activities, such as operating heavy or potentially dangerous machinery, during this initial period.

Adverse Reactions: The most common nonlaboratory adverse reactions (incidence greater than or equal to 20%) include pyrexia, CRS, hypogammaglobulinemia, infections – pathogen unspecified, musculoskeletal pain, fatigue, febrile neutropenia, hypotension, tachycardia, diarrhea, nausea, headache, chills, upper respiratory tract infection, encephalopathy, edema, dyspnea and viral infections.

Please see full Prescribing Information, including Boxed WARNINGS and Medication Guide.

References:
1. Rodriguez-Otero P, Ailawadhi S, Arnulf B, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388(11)(suppl appendix):1002‑1014. doi: 10.1056/NEJMoa2213614 2. ABECMA [package insert], Summit, NJ: Bristol-Myers Squibb Company; 2024.

References:
1. Rodriguez-Otero P, Ailawadhi S, Arnulf B, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388(11)(suppl appendix):1002‑1014. doi: 10.1056/NEJMoa2213614 2. ABECMA [package insert], Summit, NJ: Bristol-Myers Squibb Company; 2024.